Helixgate https://validator.w3.org/feed/docs/rss2.html Avalo shares spike on skin drug data; BioNTech to cut staff Home From Discovery to GMP: Building Scalable Cell Therapy Manufacturing STAT+: Oregon hospitals won’t outsource to national physician chain after all Fibrosis, IPF and the search for better therapies Increased capital boosts biotech R&D job postings, employment Winning the room: how to ace panel interviews 3 top FDA, CDC roles filled by 15 different people in less than 18 months Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity Microproteins and Peptideins Expand Boundaries of the Human Proteome Trump administration’s drug strategy is at odds with recent actions on funding, policy Amgen, AbbVie say IRA negotiations impacted Q1 sales Lilly plans new $4.5B manufacturing investment in Indiana STAT+: Administration report on most favored nation drug pricing raises new details — and questions STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline Heavy-Chain BsAbs More Manufacturable than Light-Chains Amgen, Sanofi commit nearly $600M to North American expansions Novo hikes guidance on Wegovy pill’s fast sales start CoCoGraph AI Model Generates Molecules that Comply with Rules of Chemistry Madrigal’s Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts Ipsen scuttles liver disease candidates from $952M Albireo acquisition Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma Unforced errors flummox HHS’ radical transparency bid—again Lab automation strong despite global challenges Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales GSK goes to China for $1B siRNA deal in Arrowhead’s obesity lane STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price Bayer ends multi-year M&A drought with up to $2.45B Perfuse buy Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails HHS tackles ‘overmedication’ Makary defends Replimune melanoma rejection again as FDA tensions build CellCentric raises $220M to get multiple myeloma pill to market Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening Novo Nordisk’s Q1 in four words: Pills, pricing, payments and pressure Opinion: Dr. Glaucomflecken wants to make a stink STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field Founders face pressure from all sides as biotech crawls toward recovery J&J’s Ottava surgical robot meets primary endpoints in gastric bypass study UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology Burden-aware feedback control of microbial consortia Chromosome Engineering Reveals New Locus for Fusarium Resistance in Wheat STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B Scientists boost strawberry flavor and nutrition without changing growth STAT+: Did AI really beat doctors at diagnosis? Psilocybin-Induced Brain Changes May Explain Therapeutic Effects Intercept’s next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma STAT+: Color me skeptical: Drinking gold is not an ALS cure